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Background: The aim of this study was to develop and evaluate an integrated CMR method incorporating
dynamic oximetry, blood flow and pulse-wave velocimetry to assess vascular reactivity in patients with peripheral
artery disease (PAD) and healthy controls.
Methods and results: The study population consisted of young healthy subjects (YH, 30 ± 7 yrs, N = 19),PAD (71 ±
9 yrs, N = 38), and older healthy controls (OHC, 68 ± 9 yrs, N = 43). Peripheral vascular reactivity was evaluated with
two methods, time-resolved quantification of blood flow velocity and oxygenation level in the femoral artery and
vein, respectively, performed simultaneously both at rest and hyperemia. Aortic stiffness was assessed via pulse-
wave velocity. Oximetric data showed that compared to OHC, the time-course of the hemoglobin oxygen
saturation in PAD patients had longer washout time (28.6 ± 1.2 vs 16.9 ± 1.1 s, p < 0.0001), reduced upslope (0.60 ±
0.1 vs 1.3 ± 0.08 HbO2/sec, p < 0.0001) and lower overshoot (8 ± 1.4 vs 14 ± 1.2 HbO2, p = 0.0064). PAD patients also
had longer-lasting antegrade femoral artery flow during hyperemia (51 ± 2.1 vs 24 ± 1.8 s, p < 0.0001), and reduced
peak-to-baseline flow rate (3.1 ± 0.5 vs 7.4 ± 0.4, p < 0.0001). Further, the pulsatility at rest was reduced (0.75 ±
0.32 vs 5.2 ± 0.3, p < 0.0001), and aortic PWV was elevated (10.2 ± 0.4 vs 8.1 ± 0.4 m/s, p = 0.0048).
Conclusion: The proposed CMR protocol quantifies multiple aspects of vascular reactivity and represents an initial
step toward development of a potential tool for evaluating interventions, extrapolating clinical outcomes and
predicting functional endpoints based on quantitative parameters.
Keywords: Peripheral arterial disease, Atherosclerosis, Microvascular function, Pulse-wave velocity, Blood oxygen
saturation, Phase image, Magnetic resonance oximetryBackground
Peripheral artery disease (PAD) is most commonly due
to atherosclerosis. Currently, it is estimated that approxi-
mately ten million people in the United States are
affected by PAD and the number is expected to grow as
the population ages [1]. In spite of its high prevalence
the disease often goes unnoticed because the vast ma-
jority of PAD patients have no classic claudication
symptoms, which typically occur at an advanced stage.
The initial test for diagnosing patients with clinical* Correspondence: wehrli@mail.med.upenn.edu
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reproduction in any medium, provided the orsymptoms is measurement of the ankle-brachial index
(ABI). A low ABI is a strong indicator of the presence of
PAD but a normal ABI does not rule out risk due to the
false negative rates [2], which can be understood based
on the fact that the pressure decrease in the ankle can
only be detected when lesions reduce the lumen’s diam-
eter by ≥ 70%.
Some of the manifestations of structural and functional
alterations that associated with PAD involve increases in
intimal-medial vessel wall thickness (IMT) [3], decreased
vascular compliance [4], and impaired vascular reactivity
[5]. Flow-mediated dilation (FMD) of the brachial artery
following cuff-induced ischemia [6] is a widely used
research technique for quantifying vascular reactivity.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Subject characteristics; means and standard
deviations (in parenthesis)
OHC PAD YH
N 43 38 19
Age, yrs 61 (7.6) 64.6 (7.7) 34.3* (7.5)
ABI 1.12 (0.09) 0.69* (0.15) 1.1 (0.12)
BMI, kg/m2 23 (3.0) 28* (5) 24 (4)
Systolic BP, mmHg 122 (16) 139* (26) 114 (15)
Diastolic BP, mmHg 76 (10) 80 (11) 75 (10)
MAP, mmHg 91 (10) 100* (15) 88 (11)
Heart rate, beats/min 67 (10) 73 (16) 71 (7)
HDL, mg/dL 58* (19) 46 (11) 44 (11)
Tot. Cholesterol, mg/dL 204* (36) 169 (46) 173 (26)
Asterisk indicates significant different (p < 0.0167) compared to other groups.
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(IMT), typically performed in the common carotid artery,
a procedure practiced clinically for cardiovascular disease
(CVD) risk assessment [7,8]. Major limitations of ultra-
sound are poor reproducibility due to high inter- and
intra-observer variability [9,10]. Further, the above US
measures do not target vascular territories (brachial and
carotid arteries) that are most commonly affected by PAD
(lower peripheral arteries). Increased arterial stiffness is
also associated with atherosclerosis [11-13] and may con-
tribute to microvascular dysfunction [14]. Aortic stiffness
can be estimated by quantifying PWV, typically by meas-
uring the time delay of the systolic pressure wave at some
downstream location, using pressure transducers [15,16]
placed at the two locations, e.g. carotid and common fe-
moral arteries. However, carotid-femoral PWV is merely a
surrogate [17] for aortic arch PWV because by the time
the pressure wave is detected at the carotid artery it has
already propagated through the ascending aorta.
Other non-invasive imaging techniques for quantifying
reactive hyperemia in peripheral arteries include near-
infrared spectroscopy (NIRS) [18-21], single photon
emission computed tomography [22] and CMR [23-25].
The NIRS is also a widely used research tool due to
portability and low cost. It has excellent temporal reso-
lution, is less prone to artifacts from subject motion, and
allows simultaneous monitoring of relative changes in
tissue blood flow and oxygenation. However, the spatial
resolution of NIRS is limited and it can only target the
capillary bed in relatively superficial tissues. Further, the
modality is susceptible to large inter-subject variations
in the tissue response to light, which depends on skin
color, body fat and muscle layers. CMR flow velocimetry
[23,24] has been shown to provide high spatial and tem-
poral resolution during post-occlusion hyperemia in the
femoral artery of PAD patients and healthy subjects at
1.5T. The method requires spatially-selective RF pulses
which are not widely available and migration to systems
with higher field strength may be challenging due to
increased field in homogeneity. Alternatively, micro-
vascular function can be assessed by quantifying post-
occlusive perfusion with arterial spin labeling (ASL) in
calf muscle [26]. The ASL-approach is model-dependent,
and the temporal and spatial resolutions are limited.
Here, we designed, implemented and evaluated an
integrated CMR protocol that captures quantitative
markers of vascular reactivity in the lower extremity and
the aortic arch in a single examination. The markers in-
clude parameters derived from post-occlusive blood flow
velocity and oxygenation levels (HbO2) in the femoral
vessels at high temporal resolution, and pulse-wave ve-
locity for assessing the stiffness of the aortic arch. The
method represents a significant improvement from the
authors’ pilot study [27] where only HbO2 was moni-tored during reactive hyperemia to assess peripheral vas-
cular reactivity. The present work also represents an ini-
tial step toward development of a tool for extrapolating
clinical outcomes and predicting functional endpoints
based on quantitative parameters.
Methods
Study participants
Three groups of subjects were studied: patients with PAD
(PAD; N = 38, mean ABI 0.69±0.15, mean age 64.6±7.7 yrs,
14 females), older healthy controls (OHC; N = 43, mean
ABI 1.12±0.09, mean age 61± 7.6 yrs, 25 females) and
young healthy subjects (YH; N = 19, mean ABI 1.1±0.12,
mean age 34.3±7.5 yrs, 8 females). Additional patient infor-
mation is summarized in Table 1. YH and OHC were
recruited based on their ABI (>0.90 in either leg) and me-
dical history (normotensive and without prior cardiovascu-
lar events). Patients included men and women with a
history of PAD, defined as having ABI < 0.90. Patients with
a history of myocardial infarction or stroke within three
months prior to study enrollment, or vascular surgery on
the leg selected for scanning were excluded. Written
informed consent was obtained prior to all examinations
following an institutional review board-approved protocol.
Integrated CMR assessment of vascular reactivity
The inclusion of aortic PWV quantification is motivated
by the fact that abnormal aortic stiffness can lead to
increased transmission of pressure pulsatility to peri-
pheral vessels that can affect microvascular reactivity
leading to ischemic stress [14]. However, regional PWV
of the thoraco-abdominal aorta and from iliac to femoral
arteries would be more relevant since the gradient of
PWV at the aorto-iliac bifurcation affects impedance
matching which, in turn, determines the degree of trans-
mission of pressure waves to peripheral vessels. All
CMR studies were performed at 3T field strength
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femoral artery and vein were imaged with an eight-
channel phased-array knee coil (In vivo Inc., Pewaukee,
WI) and the manufacturer’s body matrix coil (with chest
elements activated) was used to image the aorta.Quantification of reactive hyperemia in response to
cuff-induced ischemia
Post-occlusive reactive hyperemia was measured from
the time-course of blood oxygen saturation (HbO2) in
the femoral vein [27] and femoral artery flow velocity
[28]. Lower-leg ischemia was induced with a blood-
pressure cuff (Aspen Labs A.T.S. 1500 Tourniquet Sys-
tem, Littleton, CO) applied to the upper thigh at 75 mm
Hg above the subject’s systolic blood pressure but not
exceeding 250 mmHg. The cuff paradigm consisted of 2
mins baseline, 5 mins of occlusion and 6 mins of recov-
ery. During baseline (i.e. before cuff inflation) blood flow
velocity in the femoral artery and HbO2 in the femoral
vein were measured. Blood flow velocity was measured
for eight to ten cardiac cycles at a temporal resolution of
20 ms, followed by three measurements of HbO2. Data
collection was suspended during cuff occlusion and
resumed ten seconds prior to cuff deflation. Both quan-
tities were then measured simultaneously in an
interleaved fashion for 80 s while for the remaining re-
covery period (four minutes and fifty seconds) only
HbO2 was monitored.Measurement of arterial blood flow velocity
Blood flow velocity in the femoral artery was time-
resolved without cardiac gating during baseline and
hyperemia by collecting velocity-encoded projections
[28] resulting in 40-50 time points sampled within each
cardiac cycle. Imaging parameters for baseline blood flow
velocity quantification: TE/TR = 5.23/10 ms, flip angle =
15°, bandwidth = 520 Hz/pix, voxel size = 1 × 5 mm2,
matrix size = 128 and VENC = 60 cm/s (user definedFigure 1 Scout images for quantifying aortic arch PWV. a) Oblique sag
difference signal intensity plotted as a function of time showing approxima
estimated by computing the average “width” of the black parallelogram (fi
was prescribed using a graphical user interface written in C++.parameter that defines the maximum measurable
velocity).Measurement of HbO2
HbO2 in the femoral vein was estimated by field mapping,
which yields the susceptibility difference Δχ between
intravascular blood and surrounding tissue [29], where
the Δχ is proportional to (1-HbO2) and hematocrit
(determined from a blood sample). Imaging parameters
used for baseline HbO2 quantification were: TE/TR =4.3/
156.25 ms, flip angle = 25°, bandwidth = 520 Hz/pix, voxel
size = 1 × 1 × 5 mm3, matrix size = 128 × 128, yielding a
temporal resolution of 20 s during baseline.
Simultaneous quantification of HbO2 and blood flow
velocity during hyperemia
Ten seconds prior to the cuff deflation an interleaved
multi-echo GRE pulse sequence [30] was launched to col-
lect velocity-encoded projections (for velocity measure-
ment) in addition to full images (for venous HbO2
measurement). Imaging parameters during hyperemia were:
TE/TR = 5.0/39.1 ms, flip angle = 15°, bandwidth = 520 Hz/
pix voxel size = 1 × 1 × 5 mm3, matrix size = 128 × 128. Ve-
locity encoding (VENC) parameters were 125cm/s (YH and
OHC) and 80 cm/s for PADs, the rationale being that flow
in the patients would be lower than in healthy subjects.
The interleaved pulse sequence HbO2 and blood flow ve-
locity simultaneously during reactive hyperemia with tem-
poral resolution of 5 s and 120 ms, respectively.
Aortic arch pulse-wave velocity
Following the extremity protocol the patient was
prepared for aortic arch PWV quantification. The manu-
facturer’s standard body matrix coil was positioned on
the chest and multiple axial slices below the pulmonary
trunk were obtained from an oblique sagittal image of
the aorta (Figure 1a) to select an axial slice for simultan-
eously visualizing ascending and proximal descendingittal image of the aorta for prescribing an axial image; b) Complex
tely three cardiac cycles. The transit time of the pressure pulse wave is
rst full cardiac cycle around t = 2 s). The height of the parallelogram
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flow velocity, velocity-encoded projections were ob-
tained. The time-course of the complex difference (CD)
signal intensity (Figure 1b) of velocity-encoded projec-
tion signals is approximately proportional to the velocity
for large velocity encoding. The time-point of onset of
rise in systolic arterial velocity is delayed downstream,
yielding the wave-front propagation time [31]. Imaging
was performed with the following parameters: FOV =
448 mm, voxel size = 2 × 10 mm2, TE/TR = 2.6/5.0 ms,
bandwidth = 893 Hz/pixel, flip angle = 15° and VENC =
175 cm/s. After collecting a reference image (for the
purpose of identifying the vessels in CD images) 1024
pairs of velocity-encoded projections were acquired in
free-breathing mode, covering about 10–12 heart-beats at
a temporal resolution of 10 ms. The data acquisition time
was approximately 12 s. A summary of the integrated
MRI protocol is shown in Figure 2 highlighting the a-
natomic locations of the three procedures and the
parameters derived.
Data analysis
Time-resolved blood flow velocity
The phase differences between velocity-encoded pro-
jections (after removal of tissue signal) were converted
to velocity using the well-known relation between phase
’ and velocity v yielded average peak-systolic velocity vs,
peak-retrograde velocity vr and peak late-ante grade vel-
ocity va. From these parameters a measure of pulsatility,
defined as (vs - vr)/vavg, was computed. The time-course
of the hyperemic blood flow velocity (Figure 3a) was
expressed in terms of the duration of ante grade flow, Ta,
and peak-to-baseline flow rate (rQmax) (Figure 3b),
defined as the ratio, vpeak,avg/vbase,avg. The parameterFigure 2 The anatomical locations and the measured
parameters of the integrated MRI protocol for evaluating
vascular reactivity. See Data Analysis for the definition of
the parameters.vbase,avg was computed by averaging the time-resolved ve-
locity during baseline over 6–8 cardiac cycles and vpeak,avg
is the peak of the temporally averaged velocity via a
2-second sliding window during the course of hyperemia.Time-resolved HbO2 quantification
After appropriate preprocessing of the phase images
[32], HbO2 was computed from phase difference
between intra- and extravascular compartments as
described in [29,33]. Figure 4 shows representative mag-
nitude and phase difference images containing femoral
artery and vein, and the magnified phase difference
images of the vessels during hyperemia.
The time-course of HbO2 (Figure 5) characterizes vascu-
lar reactivity expressed in terms of three parameters wash-
out time, upslope and overshoot, as described previously
[27]. The washout time is the time elapsed to observe the
oxygen-depleted capillary blood at the imaging slice after
cuff deflation that occurs at t = 0. Upslope and overshoot are
defined as the mean resaturation rate during hyperemia
and the subsequent above-baseline HbO2 level, respectively.Pulse-wave velocity
The CD signals from ascending and proximal de-
scending aorta were spatially averaged along the readout
direction within the vessel boundary for each time point
and are plotted jointly to estimate the propagation time
of the wave-front (commonly known as the “foot-to-foot”
method) [31] (Figure 1b). The estimation of the wave-
front propagation time illustrated in Figure 1b is equiva-
lent to the foot-to-foot technique commonly utilized
in tonometric studies [34]. This measurement was
performed for each heart beat and averaged over the 8 to
10 cardiac cycles. The path length L of the wave-front was
then estimated from a center-line of the aorta between the
two aortic sites manually drawn on an oblique sagittal
image of the aortic arch and PWV is calculated as, L= Δt ,
where Δt is the propagation time averaged over multiple
heart-beats.
Statistical analysis
Non-parametric multiple comparisons (JMP 9.0 SAS Insti-
tute Inc.) were performed for each of the seven parameters
using a Wilcoxon test. An association was considered
significant when p < 0.0167, determined by applying a
Bonferroni correction to account for multiple comparisons.
Results
In Figure 6 baseline blood flow velocity wave form and
time-courses of post-occlusion HbO2, blood flow ve-
locity and flow rate are shown of a patient with PAD
Figure 3 a) Time-resolved post-occlusive blood flow velocity in the femoral artery of a healthy young subject. The cuff was released at
t = 0 and each vertical “spike” represents a systolic peak. The time Ta (arrow) represents the duration of the forward flow during hyperemia due to
reduction in the vascular resistance. b) Flow rate computed from the velocity data averaged over a 2-second sliding window. The dashed line
represents the baseline flow rate.
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healthy subjects (OHC and YH). The data illustrate the
differences in peripheral vascular reactivity between
three cohorts. Specifically, the velocity components of
retrograde and late-ante grade flow are better defined in
OHC compared to the patient (Figure 6a and b). The
HbO2 time-course indicates a prolonged washout time
and reduced upslope in the PAD patient compared to
the OHC (Figure 6d and e). In the post-occlusion ve-
locity time-course (Figure 6g, h), the peak average ve-
locity of the PAD patient is significantly attenuated
(resulting smaller peak flow rate as shown in Figure 6j,
k) compared to the OHC, an effect that appears to be
compensated by a prolonged recovery period [35]. In
Figure 6, the age difference between the OHC and YH is
about 45 yrs and the difference in “vascular age” is
characterized by a reduction in pulsatility (Figure 6b, c),
upslope, overshoot (Figure 6e, f ) and maximum relative
increase in the flow rate (Figure 6k, l).
Results for the seven parameters are shown in Figure 7
for each group and average values and standard errors
for each parameter and groups are summarized in
Table 2. In accordance with the data from three repre-
sentative subjects in Figure 6 the HbO2 time-courses of
PAD patients indicated longer washout time (28.6 ± 1.2
vs 16.9 ± 1.1 s, p < 0.0001), lower upslope (0.60 ± 0.1 vs
1.3 ± 0.08 HbO2/sec, p < 0.0001) and overshoot (8 ± 1.4Figure 4 Representative magnitude (a) and phase difference image (b
vein blood captured with dynamic oximetry. Image frames are displayed f
of 5 s. Note, the sixth frame corresponds to the minimum venous saturation.vs. 14 ± 1.2HbO2, p < 0.0064) compared to OHC
(Figure 7a-c). The low pulsatility index (Figure 7d, 0.75 ±
0.32 vs 5.2 ± 0.3, p < 0.0001) of PAD compared to
OHC results from reduced peak systolic velocity and at-
tenuation of retrograde flow, as illustrated in Figure 6a.
Further, the reduced average velocity during hyperemia in
PAD patients translates into smaller peak-to-baseline
flow rate (Figure 7e, 3.1 ± 0.5 vs 7.4 ± 0.4, p < 0.0001)
while increasing the duration of the post-occlusion
antegrade flow (Figure 7f, 51 ± 2.1 vs 24 ± 1.8 s,
p < 0.0001). The aortic arch PWV was elevated (Figure 7g,
10.2 ± 0.4 vs 8.1 ± 0.4 m/s, p = 0.0048) in patients
compared to OHC. Among the healthy subjects (YH and
OHC) greater upslope (Figure 7b, 1.88 ± 0.13 vs. 1.3 ±
0.08HbO2/s, p = 0.0019), overshoot (Figure 7c, 19 ± 1.9 vs.
14 ± 1.3 HbO2, p = 0.016), and as expected, smaller PWV
(Figure 7g, 5.6 ± 0.5 vs. 8.1 ± 0.4 m/s, p < 0.001) were
observed in YH compared to OHC. The correlation be-
tween stiffening of central artery and decline in peripheral
vascular reactivity is demonstrated by the inverse relation-
ship between PWV and both upslope and rQmax (Figure 8a
and b, respectively).Discussion and conclusion
In this work we have presented an integrated CMR
protocol that is able to quantify multiple physiological). c) Magnified views of the dynamic changes in the phase of femoral
or a period ranging from t = −7.5 to 67.5 s, at a temporal resolution
Note rapid change in HbO2 during passage of desaturated blood.
Figure 5 Temporal changes in HbO2 and parameters quantified
from dynamic oximetry. Cuff deflation occurs at t = 0 (vertical axis).
Figure 6 Each column of panels shows time-courses of baseline blood
and flow rate (j – l) in a patient with PAD without intermittent claudicatio
h, k) and YH (ABI = 1.04, age 26 yrs, c, f, i, l), respectively. The dashed line
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temic compliance in patients with established PAD and
healthy control subjects. The data indicate that highly
significant differences in the measured parameters bet-
ween PAD patients and OHC, as well as between the lat-
ter and the YH (Figure 7 and Table 2). Longer washout
time and increased duration of antegrade flow, Ta,
reduced upslope, overshoot, pulsatility and rQmax, as
well as elevated aortic arch PWV, are suggestive of
impaired vascular reactivity in the PAD patients relative
to age-matched control subjects. The underlying ration-
ale is that during cuff occlusion the arterial supply is
disrupted in the lower extremities, thereby leading to
gradual depletion of tissue oxygen stores. Thus, the
washout time and upslope characterize the rate at whichflow velocity (a – c), HbO2 (d – f) hyperemic arterial velocity (d – f)
n (ABI = 0.72, age 74 yrs, a, d, g, j), OHC (ABI = 1.02, age 72 yrs, b, e,
s in d-f and j-l represent upslope and baseline flow rate, respectively.
Figure 7 Average values of the parameters of (a-c) oximetry, (d-f) velocimetry and g) aortic PWV. Error bars represent standard error:
single asterisks refer to the mean difference in parameters between OHC and YH: upslope (p < 0.005), OS (p = 0.016) and PWV (p < 0.001).
Similarly, double asterisks refer to the mean difference in parameters between OHC and PAD: all p < 0.0001 except for OS (p < 0.001) and
PWV (p < 0.005).
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of the reactivity of the microvasculature since the latter
is the primary source of vascular resistance. The transi-
ent increase in arterial blood flow during hyperemia
provides further insight into vascular system’s ability to
respond to an ischemic stimulus. The brief absence of
flow reversal in healthy subjects during hyperemia
(Figure 6h, i) is likely the result of the reduction inTable 2 Average (standard error) of parameters of vascular re
Groups Washout (s) Upslope (HbO2/s) Overshoot (H
OHC 16.9 (1.1) 1.3 (0.08) 14 (1.2)
PAD 28.6 (1.2) 0.60 (0.1) 8 (1.4)
YH 15 (1.7) 1.88 (0.13) 19 (1.9)microvascular resistance, which can accommodate seven-
to nine-fold transitory increase in the flow rate [36].
Our results of aortic PWV (PAD vs. OHC) support
previous studies that have shown a correlation between
elevated aortic PWV and atherosclerosis [37,38] as well
as microvascular dysfunction [14], as shown in Figure 8.
Mitchell et al. [14] also observed that the correlation
persisted even in models that adjusted for shared riskactivity
bO2) Pulsatility Ta (s) rQmax PWV (m/s)
5.2 (0.3) 24 (1.8) 7.4 (0.4) 8.1 (0.4)
0.75 (0.32) 51 (2.1) 3.1 (0.5) 10.2 (0.4)
5.76 (0.42) 25 (2.6) 9.0 (0.6) 5.6 (0.5)




















R2=0.27; p < 0.0001
y=-0.40*rQmax+10.7
R2=0.22; p < 0.0001
Figure 8 Correlation between aortic PWV and microvascular reactivity. The parameters with the strongest correlation with PWV were
upslope and rQmax.
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beta-blocker therapy (most on metoprolol) and the aver-
age systolic blood pressure (SBP) of the patient cohort
indicated pre-hypertension (139 ± 26 mmHg), but the
SBP was higher than that of the OHC subjects (122 ± 16
mmHg, p = 0.02). Thus, it could be argued that the in-
crease in the aortic PWV among PAD patients may be
the result of elevated SBP, which is common [39,40]
among PAD patients. However, we did not find a corre-
lation between elevated SBP and aortic PWV in PAD
patients and OHC subjects as a whole. Further, all PAD
patients were on some class of anti-hypertensive medica-
tion (ACE inhibitor, beta blocker, diuretics and calcium
channel blocker) that are, in general, known to be bene-
ficial in reducing arterial stiffness [41]. The known beta
blockers that increase PWV are propanolol, bisoprolol
and possibly atenolol. In our patient cohort, only four
subjects were on atenolol and one on propanolol. Thus,
we think the medications had minimal impact on the
observed difference in the PWV between PAD and
OHC. Nevertheless, our data suggest that aortic PWV
has the potential to complement the parameters of re-
active hyperemia for assessing PAD, which is in agree-
ment with the notion that excessive transmission of
pulse pressure can have deleterious effect on micro-
vascular reactivity [14]. Lastly, MRI-based PWV quanti-
fication, which had been validated against invasive
pressure measurements [42], is more versatile as it is
able to provide regional PWV [43] with higher accuracy
[25,42] compared to the transducer-based method [44],
which is merely a surrogate marker of aortic PWV [17].
From the results of the oximetric parameters we fur-
ther observed an age-related decline in vascular reacti-
vity. Among healthy subjects the upslope and overshoot
were significantly greater in YH compared to OHC
subjects (Figure 7a, c).
There are some limitations of the techniques utilized
in the present study. The application of the cuff resultedin exclusion of patients with stent implants in the fe-
moral or popliteal artery. Thus, it was not be possible to
evaluate vascular reactivity following stent intervention.
Further, the quantification of blood flow and oxygen sa-
turation in the conduit artery and vein provides only a
global assessment (i.e. yielding no information on spe-
cific vascular territories affected in advanced disease, as
opposed to magnetic resonance angiography, for example).
The method therefore does not provide information on
tissue perfusion of specific muscle groups where an
oxygen deficit may be present. In general, the reduced
blood flow velocity and increased duration of antegrade
flow also depend on the effects of upstream stenosis (espe-
cially PAD patients) and not just on the downstream
microvascular dysfunction. Thus the velocity data of PAD
may represent the combined effects of macro- and micro-
vascular deficits. Also, it should be noted that our method
may underestimate rQmax values by 3 to 5% since we
ignored the very small change in lumen area that is not
detectable at the resolution of 1mm. PWV was quantified
from velocity-encoded projections that resolve only one
spatial dimension, which requires judicious choice of slice
and the readout direction. Also, it is not always possible to
avoid smaller overlapping vessels that are present in the
lung but, from our observations using PC-MRI, through-
plane blood flow in these vessels is negligible compared to
the ascending and descending aorta in the CD intensity
images. Lastly, we reason that 10 ms temporal resolution
is sufficient because we can extract 6–8 data points along
the upslope of the systole which lasts about 60–80 ms.
Because the upslope during this period is approximately
linear, estimation of the separation of the wave-fronts has
been shown to be robust even at the considerably lower
temporal resolution of 25–30 ms [43].
Further studies are needed to assess the reliability of
the method but the work represents an initial step to-
ward establishment of quantitative surrogate metrics for
assessing vascular reactivity in the central and peripheral
Langham et al. Journal of Cardiovascular Magnetic Resonance 2013, 15:17 Page 9 of 10
http://www.jcmr-online.com/content/15/1/17vasculature. Thus, the new technique has potential to
provide quantitative information for clinical follow-up of
individuals with PAD after drug or exercise intervention.
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